Second Phase 3 trial of ACT-132577 on systolic and diastolic blood pressure in patients with true resistant hypertension i.e. uncontrolled hypertension

Trial Profile

Second Phase 3 trial of ACT-132577 on systolic and diastolic blood pressure in patients with true resistant hypertension i.e. uncontrolled hypertension

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2017 New trial record
    • 22 May 2017 According to an Actelion Pharmaceuticals media release, the company will discuss the design of a Phase 3 program with health authorities. If successful the program will provide the basis for registration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top